Cholesterol-lowering interventions and stroke: Insights from IMPROVE-IT.

Area of Science:

• Cardiovascular Medicine
• Clinical Trials
• Lipid Metabolism

Background:

• The link between cholesterol and stroke is less clear than with myocardial infarction, complicating trial interpretations.
• Statins were historically the only lipid-lowering drugs shown to reduce stroke, leading to debate about pleiotropic effects versus cholesterol lowering.
• Previous meta-regression suggested a proportional relationship between cholesterol reduction and stroke risk reduction across interventions.

Discussion:

• The Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) provides strong evidence for cholesterol lowering's role in stroke reduction.
• Ezetimibe's effect in IMPROVE-IT demonstrates that non-statin, pure cholesterol lowering significantly impacts stroke outcomes.
• The trial's findings align closely with predictions from previous meta-analyses, reinforcing the cholesterol-stroke risk relationship.

Key Insights:

• A 1% reduction in total cholesterol is associated with a 0.8% relative risk reduction in stroke.
• IMPROVE-IT showed a 13.3% total cholesterol reduction led to a hazard ratio of 0.86 for stroke.
• Pure cholesterol lowering, exemplified by ezetimibe, is a validated strategy for stroke risk reduction.

Outlook:

• These findings are crucial for predicting outcomes in ongoing trials of PCSK9 inhibitors and cholesterol ester transfer protein inhibitors.
• The results support a unified understanding of lipid-lowering mechanisms in cardiovascular disease prevention.
• Further research can leverage this understanding to refine therapeutic strategies for stroke prevention.